All In Biotech

Free tool

FAERS Monitor: Enjaymo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761164 or its brand name (Enjaymo, Sutimlimab-Jome). Reports on generic versions are filed under their own applications.

Reports

321

Serious

180

56% of reports

Hospitalization

71

Death reported

54

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use39
  • haemoglobin decreased23
  • arthralgia20
  • fatigue18
  • death16
  • haemolysis16
  • condition aggravated15
  • drug ineffective13
  • headache13
  • covid-1912
  • cyanosis11
  • nausea11
  • inappropriate schedule of product administration10
  • pain10
  • dyspnoea9

Reports by year received

View as table
YearReports
202234
202359
202473
202572
202683

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,838 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
haemolysisSignal16136.084.32,008
cyanosisSignal1145.925.7439
haemoglobin decreasedSignal2314.79.9281
covid-19Signal124.52.629
inappropriate schedule of product administrationSignal103.62.017
condition aggravatedSignal153.22.021
arthralgiaSignal203.22.128
off label useSignal392.92.249
fatigue181.51.03
headache131.40.81
death161.20.80
pain101.10.60
dyspnoea91.00.50
nausea110.90.50
drug ineffective130.60.42

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.